BH17 Bridging the Gap: Identifying Dual-Targeting Therapies for Patients with Alopecia Areata and Coexisting Immune-Mediated Inflammatory Diseases

The document reviews the potential for dual-targeting therapies for alopecia areata (AA) and coexisting immune-mediated inflammatory diseases (IMIDs) like Crohn disease, atopic dermatitis, and psoriasis. It highlights the overlap in inflammatory pathways and treatments, suggesting opportunities for drug repositioning. Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise for treating both AA and other IMIDs. Other therapies like amlitelimab and ustekinumab are in various trial phases for AA. The study emphasizes the importance of multidisciplinary team meetings and real-world evidence integration to navigate the complexity of emerging therapies. The Global Registry of Alopecia areata disease Severity and treatment Safety (GRASS) UK aims to provide high-quality data to enhance patient care and outcomes.